How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

100 results for

Symlin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

of the investigational drug, whichever is greater) of screening Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications: Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening Systemic corticosteroids

2009 Clinical Trials

62. Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

of screening or is planning to donate during the study has had a major surgery or blood transfusion within 2 months before screening is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin has received an investigational drug within 1 month before screening has allergies or hypersensitivity to any component of the study drug has previously had

2008 Clinical Trials

63. Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) Study of Using Symlin Alongside Insulin in a Multiple Injection Port The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00790699 Recruitment Status : Terminated (Lack of patient population) First Posted : November 13, 2008 Last Update Posted : November 17, 2011 Sponsor: Texas Diabetes & Endocrinology

2008 Clinical Trials

64. Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: 1 Drug: Placebo placebo pramlintide and placebo metreleptin twice daily Experimental: 2 Pramlintide and 1.25mg Metreleptin Drug: Pramlintide and Metreleptin Subcutaneous injection, twice daily Other Name: Symlin Experimental: 3 Pramlintide and 2.5mg Metreleptin Drug: Pramlintide and Metreleptin Subcutaneous injection, twice daily Other Name (...) : Symlin Experimental: 4 Pramlintide and 5.0mg Metreleptin Drug: Pramlintide and Metreleptin Subcutaneous injection, twice daily Other Name: Symlin Outcome Measures Go to Primary Outcome Measures : LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable Population [ Time Frame: Original Study Baseline to Week 52 ] Original study DFA102 (NCT00673387) baseline refers to Visit 5 (Day 1). If Day 1

2008 Clinical Trials

65. Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

to screening: Insulin; Sulfonylureas; Alpha-glucosidase inhibitors (e.g., Glyset® [miglitol] or Precose® [acarbose]); Meglitinides (e.g., Prandin® [repaglinide] or Starlix® [nateglinide]); Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ [sitagliptin], Galvus® [vildagliptin]); Symlin® (pramlintide acetate). Have had an organ transplant. Have donated blood within 30 days of screening. Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly. Have

2008 Clinical Trials

66. Metabolomic Profiling of Novel Mediators of Vascular Function

Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Sampling Method: Non-Probability Sample Study Population community sample Criteria Inclusion Criteria: Adults age 18 or older Type 2 diabetes mellitus Exclusion Criteria: Type 1 diabetes mellitus Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin [pramlintide]), or incretin mimetics (Byetta [exenatide]) Pregnancy Uncontrolled hypertension

2008 Clinical Trials

67. Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

of Symlin (pramlintide acetate) and/or Byetta (exenatide) within the past 12 weeks Unstable diabetes control and evidence of severe complications of diabetes mellitus (ie, autonomic neuropathy) Exposure to any investigational product(s) in the past 12 weeks For subjects with type 2 diabetes mellitus: In subjects taking metformin, serum creatinine > 1.4 mg/dL in female subjects and > 1.5 mg/dL in male subjects Contacts and Locations Go to Information from the National Library of Medicine To learn more

2008 Clinical Trials

68. Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

study or has received prior treatment with pramlintide (SYMLIN®) or calcitonin Has received any investigational drug within 1 month or within a period corresponding to five times the half-life of the investigational drug, whichever is greater, before study start Has donated blood within 2 months before study start or is planning to donate blood during the study Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2008 Clinical Trials

69. Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

. ClinicalTrials.gov Identifier: NCT00732147 Recruitment Status : Withdrawn (Sponsor could not fund.) First Posted : August 11, 2008 Last Update Posted : June 5, 2012 Sponsor: University of Maryland Collaborator: Amylin Pharmaceuticals, LLC. Information provided by: University of Maryland Study Details Study Description Go to Brief Summary: Diabetes affects almost 21 million people in the United States. In this study we will test a drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat (...) given subcutaneously before each meal x 3. Experimental: 1 Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period. Drug: Pramlintide acetate 120 micrograms given subcutaneously before each meal X 3. Other Name: Symlin Outcome Measures Go to Primary Outcome Measures : Endogenous glucose production [ Time Frame: 18 hours ] Secondary Outcome Measures : Endogenous VLDL-Triglyceride production [ Time Frame: 18 hours ] Eligibility Criteria Go to Information from the National

2008 Clinical Trials

70. Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

medications. Has previously received treatment with metreleptin or pramlintide in a clinical study or has received prior treatment with pramlintide (SYMLIN®). Has received any investigational drug within 30 days or within a period corresponding to 5 half-lives of that drug, whichever is greater, prior to this study starting. Has had a major surgery or a blood transfusion, or has donated blood over the past 2 months or is planning to donate blood during the study. Has had liposuction, abdominoplasty

2008 Clinical Trials

71. Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION

[acarbose]) Meglitinides (e.g., Prandin® [repaglinide] or Starlix® [nateglinide]). Byetta® (exenatide BID formulation) Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ [sitagliptin], Galvus® [vildagliptin]) Symlin® (pramlintide acetate). Have had an organ transplant. Have donated blood within 30 days of screening. Have previously completed or withdrawn from this study or any other study investigating exenatide once weekly. Have received treatment within the last 30 days with a drug that has

2008 Clinical Trials

72. Evaluate Safety of TI in Diabetic Subjects With Moderate Obstructive Pulmonary Disease (Asthma and COPD)

for ≥ 2 days Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs. Greater than 2 hospitalizations or ER or urgent care visits or required >3 courses of systemic steroid in the past 12 months for respiratory illness Use of Symlin® (pramlintide acetate) within the preceding 90 days Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between

2008 Clinical Trials

73. A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

type of anti-diabetic therapy other than metformin, sulfonylurea, meglitinide and alpha glucosidase inhibitors within the preceding 12 weeks [ie, thiazolidinediones (TZDs), dipeptyl peptidase inhibitors (DPP-IV), Symlin (pramlintide acetate) and or Byetta (exenatide)]. Exclusion Criteria: Exposure to any investigational medications or devices within the previous 90 days prior to trial entry or participation in another clinical trial while participating in this trial. Use of any prescription

2008 Clinical Trials

74. BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

study Exclusion Criteria: Pregnancy Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months prior to screening History of symptomatic heart valve disease Serious or unstable current or past medical conditions Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2008 Clinical Trials

75. A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione

-45 kg/m2, inclusive HbA1c level of 7.50 - 10.00%, inclusive If a female of childbearing potential, willing to utilize contraception from Screening through 4 weeks after the last dose of study drug Exclusion Criteria: Treatment with insulin, sulfonylurea, DPP-4 inhibitors, Symlin® and/or GLP-1 analogues ≤ 3 months prior to the Screening Severe hypoglycemia ≤ 60 days prior to the Screening visit or currently diagnosed with having hypoglycemia unawareness History of peptic ulcer(s

2008 Clinical Trials

76. A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION

with any of the following treatment-excluded medications: Exenatide (BYETTA®) or any Dipeptidyl peptidase-4 DPP-4)inhibitor, sulfonylurea (SU), thiazolidinedione (TZD), or glucagon-like peptide (GLP)-1 analog within 3 months prior to study start Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of study start Insulin within 2 weeks of study start or for more than 1 week within 3 months of study start Systemic corticosteroids by oral, intravenous

2008 Clinical Trials

77. Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes

insulin ± OA(s) for at least 3 months (Subjects may also be treated with exenatide [Byetta] or pramlintide [Symlin]. If on concomitant metformin, has serum creatinine < 1.5 mg/dL (male) or <1.4 mg/dL (female); If female, has a negative urine pregnancy test Exclusion Criteria: Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months; Has clinical cardiovascular disease (CVD) as evidenced by prior myocardial infarction, stroke, arterial revascularization

2008 Clinical Trials

78. Continuous Subcutaneous Infusion of Pramlintide and Insulin

2006 Actual Primary Completion Date : November 2007 Actual Study Completion Date : November 2007 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Intervention Details: Drug: Pramlintide Basal and bolus pramlintide subcutaneous infusion Other Name: Symlin Outcome Measures Go to Primary Outcome Measures : Area under the curve for glucose [ Time Frame: 4 hrs ] Secondary Outcome Measures : glucagon and gastric emptying [ Time Frame

2006 Clinical Trials

79. Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

. FEV1 ≥ 70% of NHANES III predicted; TLC) ≥ 80% of predicted (Intermountain Thoracic Society); DLCO uncorrected ≥ 70% of predicted Exclusion Criteria: Total daily dose of insulin ≥1.4 IU/kg body weight Treatment with any sulfonylureas and/or meglitinides and/or alpha-glucosidase inhibitors within the preceding 8 weeks Treatment with pramlintide acetate (Symlin®), and/or any incretins (e.g., exenatide [Byetta®]) within the preceding 8 weeks Unstable diabetes mellitus control, defined as 2 or more

2006 Clinical Trials

80. A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00240253 Recruitment Status

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>